An observational study in Biliary Atresia, sponsored by Weibing Tang. Recruiting at 1 site in China. Open to participants aged 6 Months to 6 Years. Per ClinicalTrials.gov, last updated 2023-06-18.
Sponsored by Weibing Tang · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Biliary Atresia with a site in China — 7 open to participants now, 9 under way, 1 of them phase 3. Biliary Atresia · China.
Among the 21 studies in Biliary Atresia with a site in China, this one is the 8th largest by planned enrollment of the 10 observational ones that give a count, is the only one that started in 2017, is one of 10 observational ones, and was the 15th registered.
78 studies on the registry are indexed under Biliary Atresia; 26 are open to participants now.
Browse Biliary Atresia studies →7 of the 21 studies in Biliary Atresia with a site in China are open now. Recruiting first, the newest first:
Tongji Hospital · Sites in China
Ages 1 days–3 mo
Children's Hospital of Fudan University · Sites in China
Children's Hospital of Fudan University · Sites in China
Ages 14 days–90 days
Children's Hospital of Fudan University · Sites in China
Ages up to 3 mo
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 1 days–3 mo · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 21 Biliary Atresia studies recruiting now, 3 (14%) set no upper age limit and 18 (86%) stop at 75 or younger; 21 take children under 18; 6 take healthy volunteers.
This study: 6 Months to 6 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 3 · Phase 4 2
First in 2014; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 120 across 33 observational studies indexed under Biliary Atresia.
Median enrollment 160 across the 11 interventional studies, 200 across the 10 observational. Of the 6 that completed or were terminated, 2 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 21 have an industry lead sponsor. The 10 most frequent:
Weibing Tang is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Weibing Tang has 1 study filed under Biliary Atresia — fewer than ten, so there is no comparison to draw.
1 of the studies in Biliary Atresia with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07940543Nanjing Children's HospitalConstruction of a Liver Metabolic Atlas in Biliary Atresia Based on Raman Spectroscopic Imaging | 2027-03-10 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies in Biliary Atresia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Many factors have been proven that may affect NLS in BA patients after KP;however,the early predictors for NLS were not be finally detected.This study was designed to evaluate and identify the preoperative and early postoperative factors associated with NLS for early prediction in BA patients after KP.
Biliary atresia (BA) is the most common cause of neonatal cholestasis, occurring in approximately 1: 8000 to 1:15000 in Asian populations compared with those in Europe and the USA, with a ratio of 1: 1.56 in males and females.Until now, Kasai procedure(KP) remains the preferred treatment for biliary BA;however,nearly 60-70% patients after KP need liver transplants to achieve long-term survival.Therefore, it is meaningful to seek and analyze the factors affecting the native liver survival(NLS) in BA patients with KP for prediction. Luckily, A lot of studies have designed to seek the risk factors for death or liver transplants in BA patients after KP,and many factors have been proven that may affect NLS,including old age at KP,low gamma-glutamyl transpeptidase(GGT) level,Cytomegalovirus(CMV) Infection,early jaundice clearance(JC) and postoperative cholangitis(PC),etal.However,the predictors for NLS were not be finally detected.Otherwise,the safety of liver transplants has been improved in the past few years and performing liver transplant in young infants has been proven to be feasible.Then,it is important to seek early NLS predictors for counseling the necessity and timing of liver transplant.Unfortunately,early predictors of NLS focus on preoperative and early postoperative period after KP were insufficient.
This study is primarily designed to evaluate and identify the preoperative and early postoperative factors associated with NLS for early prediction in BA patients after KP.
patients with Biliary atreisa and were performed with kasai procedures
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Biliary Atresia(BA) patients performed with Kasai Procedure patients completed the follow-up>6 months
Exclusion Criteria:
BA patients without KP patients lost of follow-up BA patients with other severe complications lead to death
All KPs were performed by a medical team. This technique involved creation of a 35-40 cm Roux loop to facilitate biliary drainage. After dissection of the hepatic vasculature at the hilum and excision of the hilar plate, hepaticojejunostomy was performed as an anastomosis extending from the bifurcation of the right hepatic artery into anterior and posterior branches to the Rex confluence of the left portal vein with the obliterated umbilical vein.
NLS rate
native liver survival rate
Time frame: through study completion, an average of 3 years
age at KP
age at kasai procedure
Time frame: through study completion, an average of 3 years
PC
post cholangitis
Time frame: through study completion, an average of 3 years
JC
jaudiance clearance
Time frame: through study completion, an average of 3 years
Plan to share: No — The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
No publications or documents are linked to this record.
Started May 2017 (actual). Primary completion is estimated for Jul 2023, 73 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Weibing Tang